期刊文献+

慢性肾小球疾病中25-羟维生素D_3水平的改变及意义 被引量:2

Changes and significance of serum 25(OH)D_3 in patients with chronic glomerular diseases
原文传递
导出
摘要 目的探讨慢性肾小球疾病患者25-羟基维生素D3[25(OH)D3]水平的改变及意义。方法慢性肾小球疾病患者823例中,肾病综合征122例(14.7%),原发肾小球疾病463例(55.7%),高血压肾病35例(4.2%),糖尿病肾病50例(6.0%),狼疮性肾炎和血管炎导致的肾脏损害42例(5.1%),其他病因导致的肾脏损害111例(13.4%)。比较六组患者血清25(OH)D3水平、24-h尿蛋白及血白蛋白水平的差异。结果全组患者血清25(OH)D3水平为(28.8±21.6)nmol/L,白蛋白为(35.1±8.6)nmol/L,24-h尿蛋白(2.33±3.42)g。六组患者间血清25(OH)D3、白蛋白及24-h尿蛋白均存在统计学差异(P<0.05);肾病综合征组血清25(OH)D3最低[(12.7±10.1)nmol/L],24-h尿蛋白最高[(6.03±5.50)g]。结论在各类慢性肾小球疾病中,肾病综合征患者的25(OH)D3缺乏最为严重。 Objective To explore the changes and significance of serum 25-hydroxy vitamin D3 [25(OH)D3] in the patients with chronic glomerular diseases. Methods A total of 823 patients with chronic glomerular diseases was divided into 6 groups of A (nephrotic syndrome, 122 cases), B (primaYy glomerular disease, 463 cases), C (hypertensive nephropathy, 35 cases), D (diabetic nephropathy, 50 cases), E(lupus nephritis and vasculitis, 42 cases) and F(kidney damage resulted from the other causes, 111 cases). Serum level of 25 (OH)D3,24-hour urine protein and serum albumin were compared among 6 groups. Results In 823 patients, serum 25(OH)D3 was (28. 8±21.6) nmol/L, serum albumin was (35.1±8.6) nmol/L,and 24-hour urine protein was (2.33±3.42) g,which were all significantly different among 6 groups(P〈0. 05). Serum 25(OH)D3 in group A was (12.7±10. 1) nmol/L, which was the lowest among 6 groups(P〈0. 05), and 24-hour urine protein in group A was (6.03±5.50) g,which was the highest among 6 groups(P〈0. 05). Conclusion Of different kinds of chronic glomerular diseases, the deficiency of serum 25 (OH)D3 is of most severity in the patients with nephrotic syndrome.
出处 《江苏医药》 CAS 北大核心 2014年第14期1685-1687,共3页 Jiangsu Medical Journal
关键词 慢性肾小球疾病 25-羟基维生素D3 Chronic glomerular diseases 25-Hydroxy vitamin D3
  • 相关文献

参考文献3

二级参考文献29

  • 1廖二元.维生素D制剂的药理机制与临床应用[J].中南药学,2003,1(2):98-102. 被引量:12
  • 2刘桂萍.1,25—二羟基维生素D_3的研究进展[J].生物学教学,1994,19(4):4-6. 被引量:3
  • 3张焱,程学新,刘颙颙,王雪松,张宝文.光化学合成维生素D[J].精细与专用化学品,2005,13(5):5-7. 被引量:13
  • 4何彩平.维生素D的生物效应与疾病[J].重庆医学,1995,24(1):56-57. 被引量:1
  • 5Weng FL,Shults J,Herskovitz RM,et al.Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission[J].Pediatr Nephrol,2005,20(1):56-63.
  • 6Bak M,Serdaroglu E,Guclu R.Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome[J].Pediatr Nephrol,2006,21(3):350-354.
  • 7Isakova T,Gutiérrez OM,Patel NM,et al.Vitamin D deficiency,inflammation,and albuminuria in chronic kidney disease:complex interactions[J].J Ren Nutr,2010[Equb ahead of print].
  • 8Xiao HQ,Shi W,Liu SX,et al.Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats[J].Clin Exp Pharmacol Physiol,2009,36(7):682-689.
  • 9Hamano T.Vitamin D deficiency in CKD patients[J].Clin Calcium,2007,17(5):718-724.
  • 10Fishbane S,Chittineni H,Packman M,et al.Oral paricalcitol in the treatment of patients with CKD and proteinuria:a randomized trial[J].Am J Kidney Dis,2009,54(4):647-652.

共引文献45

同被引文献12

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部